Recent Reports


2011-11-14: Biotechnology and Pharmaceuticals Report
5 leading Analysts; and top management from 4 Sector Firms examine this industry.
Order this Report
More Information

2011-10-31: Health Care IT Report
4 leading Analysts; and top management from 5 Sector Firms examine this industry.
Order this Report
More Information

2011-10-17: Medical Research, Diagnostic Substances & Life Science Tools Report
4 leading Analysts; and top management from 3 Sector Firms examine this industry.
Order this Report
More Information

2011-10-03: Medical Real Estate Report
3 leading Analysts; and top management from 3 Sector Firms examine industry.
Order this Report
More Information

2011-07-11: Medical Devices Report
5 leading Analysts; and top management from 12 Sector Firms examine this industry.
Order this Report
More Information

2011-06-27: Health Care IT Report
6 leading Analysts; and top management from 9 Sector Firms examine this industry.
Order this Report
More Information

2011-06-13: Medical Research, Diagnostic Substances & Life Science Tools Report
5 leading Analysts; and top management from 3 Sector Firm examine this industry.
Order this Report
More Information

2011-04-04: Biotechnology and Pharmaceuticals Report
3 leading Analysts; and top management from 5 Sector Firms examine this industry.
Order this Report
More Information

2011-01-24: Medical Devices Report
3 leading Analysts; and top management from 9 Sector Firms examine this industry.
Order this Report
More Information

Search TWST Online

TWST Newsletter

Give us your email address and receive the TWST Newsletter.


Company Interview Excerpt
AmexDrug Corporation - Jack Amin


Full article published: 11/02/2009


For Subscribers

Get this article online now!

Order just this article
TWST: Let's begin with a brief overview of the history and evolution of AmexDrug.
Mr. Amin: AmexDrug Corporation is actually a vertically integrated pharmaceutical and cosmeceutical manufacturing company. We have subsidiaries, such as BioRX Pharmaceuticals, Allied Medical Wholesale, Dermagen, Inc., which develop, manufacture, market and distribute pharmaceutical and innovative skin care products within the United States.

TWST: Please explain the makeup of your customer base and who your direct competition is today.
Mr. Amin: Basically, our customer base are independent pharmacies, wholesalers and chain drug stores. Within a year, we're planning to distribute our product, which is trademarked as SPONIX within the retail markets such as CVS, Kroger's, Walgreens. We would like to get our products within those stores within next year or so.

TWST: How has the company been managing during this downturn? You're based on the West Coast, is that right?
Mr. Amin: That's correct. We're in Los Angeles, California.
Actually, we're doing very well; we're doing better than last year and the year before. Our sales are going up, according to our last quarter. We had, I believe, a 50% to 60% jump on our revenue, and this quarter we're going to have another jump. We're working against the downturn. So we're going up, our sales are going up, our margin is going up and we have added prescription packaging products to our line as well. We have had more distribution to stores, to independent pharmacies nationwide as we're picking up a few smaller chain drug stores. So we've been doing pretty well.

 

Tickers included in this excerpt: AXRX.OB

 

For more information call (212) 952 7433. The Wall Street Transcript does not endorse any of the comments made by interviewees, and does not make stock recommendations.